Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Gross Margin (2020 - 2025)

Neuroone Medical Technologies' Gross Margin history spans 10 years, with the latest figure at 54.2% for Q4 2025.

  • For Q4 2025, Gross Margin fell 465.0% year-over-year to 54.2%; the TTM value through Dec 2025 reached 54.87%, up 721.0%, while the annual FY2025 figure was 56.51%, 2525.0% up from the prior year.
  • Gross Margin reached 54.2% in Q4 2025 per NMTC's latest filing, down from 55.77% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 58.85% in Q4 2024 to a low of 115.81% in Q1 2021.
  • Average Gross Margin over 5 years is 4.76%, with a median of 26.67% recorded in 2023.
  • Peak YoY movement for Gross Margin: skyrocketed 10577bps in 2023, then crashed -465bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 38.81% in 2021, then surged by 72bps to 10.74% in 2022, then soared by 354bps to 27.24% in 2023, then soared by 116bps to 58.85% in 2024, then fell by -8bps to 54.2% in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Gross Margin are 54.2% (Q4 2025), 55.77% (Q3 2025), and 53.94% (Q2 2025).